A Phase 2 Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adults with Cancer
Eli Lilly and Company (Sponsor)
Summary
Eli Lilly is conducting a Phase 2 trial of LY3537021, a glucose-dependent insulinotropic peptide (GIP) receptor agonist, for chemotherapy-induced nausea and vomiting (CINV). The study is enrolling 204 adult cancer patients receiving cisplatin or anthracycline-cyclophosphamide (AC) chemotherapy, comparing LY3537021 + standard antiemetics vs. placebo + standard antiemetics. This represents a novel application of incretin-based peptides in supportive oncology care.
Clinical Significance
This trial extends incretin peptide therapy beyond metabolic disease into supportive cancer care. If successful, a GIP agonist could represent a first-in-class mechanism for CINV management — a significant unmet need affecting millions of chemotherapy patients worldwide. It also signals the expanding clinical applications of incretin-family peptides.
Key Findings:
- Phase 2, double-blind, placebo-controlled design (n=204 estimated)
- LY3537021 administered subcutaneously prior to chemotherapy
- Standard of care: 5-HT3 antagonist, NK1 antagonist, dexamethasone
- Chemotherapy types: Cisplatin or Anthracycline + Cyclophosphamide (AC)
- Currently recruiting, primary completion estimated September 2026
Clinical Takeaway: This Eli Lilly trial marks the expansion of incretin peptides (beyond GLP-1) into supportive oncology. Clinicians should watch for results, as GIP agonists could add a new mechanism to the CINV management toolkit.
Links:
Свързани изследвания
Peptide Angio-3 Attenuates Pulmonary Fibrosis Via Modulation of Coagulation Factor Xa-PAR-1 Signaling Axis
Angio-3, a 10-residue peptide derived from human plasminogen kringle 3, demonstrated significant ant…
Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review
A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, …
Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial
The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing signif…
Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial
Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight redu…